American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: http://www.sciepub.com/journal/ajidm Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
Go
American Journal of Infectious Diseases and Microbiology. 2013, 1(4), 64-69
DOI: 10.12691/ajidm-1-4-2
Open AccessReview Article

Invasive Fungal Infections: A Comprehensive Review

K V Ramana1, , Sabitha Kandi2, Venkata Bharatkumar P3, CH V Sharada4, Ratna Rao4, Ratna Mani4 and Sanjeev D Rao1

1Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Andhrapradesh, India

2Department of Biochemistry, Chalmeda Anandarao Institute of Medical Sciences, Karimnagar, Andhrapradesh, India

3Department of Biochemistry, Vaidehi Institute of Medical Sciences, and Research Centre, Bangalore

4Department of Microbiology, Apollo Health City, Jubilee Hills, Hyderabad, Andhrapradesh, India

Pub. Date: June 24, 2013

Cite this paper:
K V Ramana, Sabitha Kandi, Venkata Bharatkumar P, CH V Sharada, Ratna Rao, Ratna Mani and Sanjeev D Rao. Invasive Fungal Infections: A Comprehensive Review. American Journal of Infectious Diseases and Microbiology. 2013; 1(4):64-69. doi: 10.12691/ajidm-1-4-2

Abstract

Fungi are a versatile group of microorganisms which can be freely present in the environment, be a part of the normal flora of human and animals and have the ability to cause mild superficial infections to severe life threatening invasive infections. Invasive fungal infections (IFI’s) are those infections where fungi have invaded in to the deep tissues and have established themselves resulting in prolonged illness. IFI’s usually are seen in debilitated and immunosuppressed individuals. There are many reports of IFI’s even in immunocompetent individuals thus making IFI’s a potential threat in the present century. Fungi are saprophytic microorganisms which have evolved mechanisms to survive in the mammalian hosts. Most of the fungal infections have been accidental and systemic fungal infections are a rarity that may result in high mortality. In systemic fungal infections the outcome of the disease depends more on the host factors rather than the fungal virulence. Immune response to fungal infections is a complex subject where in fungi invading goes unrecognised by the immune system and that invasive fungal infections can result in severe inflammatory reactions resulting in morbidity and mortality. From being uncommon during the earlier part of the 20th century when the world was plagued with bacterial epidemics, fungi have evolved as a major global health problem.

Keywords:
Invasive Fungal Infections (IFI’s) immunocompromised individuals opportunistic pathogens predisposing factors for IFI’s

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 1

References:

[1]  S. Ascioglu, J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning,1 J. P. Donnelly et al. Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus. Clinical Infectious Diseases 2002; 34:7-14.
 
[2]  Guo-Hao Xie, Xiang-Ming Fang, Qiang Fang, Xin-Min Wu, Yu-Hong Jin, Jun-Lu Wang et al. Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients. Critical Care 2008, 12:R5.
 
[3]  Edwards JE Jr. Invasive Candida infections. N Engl J Med. 1991; 324: 1060-1062.
 
[4]  Ramana KV, Kumar MV, Rao SD, Akhila R, Sandhya, et al. Pulmonary Cryptococcosis Secondary to Bronchial Asthma Presenting as Type I Respiratory Failure- A Case Report with Review of Literature. Virol Mycol, 2012 1:107.
 
[5]  Chandrasekar PH, Alaganden G, Manavathu E. Aspergillus: an increasing problem in tertiary care hospitals. Clinical Infectious Diseases, 2000; 30, 984-985.
 
[6]  Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50:1091-1100.
 
[7]  Michaela Lackner and G Sybren de Hoog. Scedosporium spp.: Emerging Agents of Systemic Disease. J Invasive Fungal Infect 2011; 5(2):43-7.
 
[8]  Tania A Baban, Roy A Raad, Dima Dandachi, Souha S Kanj, and Zeina A Kanafani. Three Cases of Mucormycosis from the Middle East: Different Risk Factors Leading to Different Outcomes. J Invasive Fungal Infect 2011; 5(4):118-22.
 
[9]  Rodrick Kabangila, Kilonzo Semvua, Peter Rambau, Kahima Jackson, Stephen E Mshana, Hyasinta Jaka and Robert N Peck. Pulmonary histoplasmosis presenting as chronic productive cough, fever, and massive unilateral consolidation in a 15-year-old immune-competent boy: a case report Journal of Medical Case Reports 2011, 5:374.
 
[10]  Cruz R, Vieille P, Oschilewski D. Sporothrix globosa isolation related to a case of lymphocutaneous sporotrichosis. Rev Chilena Infectol. 2012; 29(4):401-5.
 
[11]  Stephenie Y. N. Wong and K. F. Wong, “Penicillium marneffei Infection in AIDS,” Pathology Research International, vol. 2011, Article ID 764293, 10 pages, 2011.
 
[12]  Basiri K, Meidani M, Rezaie F, Soheilnader S, Fatehi F. A rare case of Trichosporon brain abscess, successfully treated with surgical excision and antifungal agents. Neurol Neurochir Pol. 2012; 46(1):92-5.
 
[13]  Barber GR, Brown AE, Kiehn TE, et al. Catheter -related Malassezia furfur fungaemia in immuocompromised patients. Am J Med. 1993; 95: 365-370.
 
[14]  Hattori H, Inoue C, Tomita Y, Kanbe T (2007) A case of oral geotrichosis caused by Geotrichum capitatum in an old patient. Jpn J Infect Dis 60: 300-301.
 
[15]  Chandler F, Watts J.  Mycotic, Actinomycotic, and Algal Infections.  In Kissane J (ed) Anderson’s Pathology, 9th ed. C.V. Mosby, St. Louis, 1996: 391-432.
 
[16]  Hahn-Ast C, Glasmacher A, Mückter S, et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother. 2010; 65:761-768.
 
[17]  Patrick Vandeputte, Selene Ferrari and Alix T coste. Antifungal resistance and new strategies to control fungal infections. International Journal of Microbiology. 2012; 1-26.
 
[18]  Laura H. Hogan, Bruce S. Klein, and Stuart M. Levitz. Virulence Factors of Medically Important Fungi. Clin Microbiol rev 1996; 9(4): 469-488.
 
[19]  Clara M. Bien and Peter J. Espenshade. Sterol Regulatory Element Binding Proteins in Fungi: Hypoxic Transcription Factors Linked to Pathogenesis Eukaryotic Cell 2010, 9(3):352.
 
[20]  OC Yoder and B Gillian Turgeon. Fungal genomics and pathogenicity. Current Opinion in Plant Biology 2001, 4:315-321.
 
[21]  Thiel, R. Systemic mycoses: An overview for modern natural health professionals. The Original Internist, 2010; 17(3):119-12.
 
[22]  Walsh T, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections: All neutropenic patients are not the same. Clinical Infectious Diseases, 1994; 18: 793-798.
 
[23]  Segal BH, Romani LR. Invasive aspergillosis in chronic granu- lomatous disease. Med Mycol 2009; 47:S282-S290.
 
[24]  Lenka Bašková andVladimír Buchta. Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach. Folia Microbiol (2012) 57:421-430.
 
[25]  Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Rácil Z, Richardson M, Rogers TR Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66:i15-i24.
 
[26]  El-Mahallawy HA, Shaker HH, Ali Helmy H, Mostafa T, Razak Abo-Sedah A. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol 2006; 44:733-739.
 
[27]  Park C, Kwon EY, Shin NY, Choi SM, Kim SH, Park SH, Lee DG, Choi JH, Yoo JH. Evaluation of nucleic acid sequence based amplification using fluorescence resonance energy transfer (FRET-NASBA) in quantitative detection of Aspergillus 18S rRNA. Med Mycol 2011; 49:73-79.
 
[28]  Spiess B, Seifarth W, Hummel M, Frank O, Fabarius A, Zheng C, Mörz H, Hehlmann R, Buchheidt D DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007; 45:3743-3753.
 
[29]  Borman AM, Linton CJ, Oliver D, Palmer MD, Szekely A, Johnson EM. Rapid molecular identification of pathogenic yeasts by pyrosequencing analysis of 35 nucleotides of internal transcribed spacer 2. J Clin Microbiol 2010; 48:3648-3653.
 
[30]  Bille E, Dauphin B, Leto J, Bougnoux ME, Beretti JL, Lotz A, Suarez S, Meyer J, Join-Lambert O, Descamps P, Grall N, Mory F, Dubreuil L, Berche P, Nassif X, Ferroni A. MALDI-TOF MS Andromas strategy for the routine identification of bacteria, mycobacteria, yeasts, Aspergillus spp. and positive blood cultures. Clin Microbiol Infect. 2012.
 
[31]  J. M. Benson and M. C. Nahata, “Clinical use of systemic antifungal agents,” Clinical Pharmacy, 1988; 7(6): 424-438.
 
[32]  J. P. Barrett, K. A. Vardulaki, C. Conlon et al., “A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations,” Clinical Therapeutics, 2003; 25(5): 1295-1320.
 
[33]  F. Marco, M. A. Pfaller, S. A. Messer, and R. N. Jones, “Anti- fungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi,” Medical Mycology, 1998; 36(6): 433-436.
 
[34]  Mary Ann Jabra-Rizk, William A. Falkler, and Timothy F. Meiller. Fungaln Biofilms and Drug Resistance. Emerging infectious Diseases. 2004; 10 (1): 14-19.
 
[35]  He´ le` ne Tournu and Patrick Van Dijck. Candida Biofilms and the Host: Models and New Concepts for Eradication. International Journal of Microbiology, 2012, 1-16.
 
[36]  Mary Ann Jabra-Rizk, William A. Falkler, and Timothy F. Meiller. Fungaln Biofilms and Drug Resistance. Emerging infectious Diseases. 2004; 10 (1): 14-19.
 
[37]  Marcel Wüthrich, George S. Deepe Jr. and Bruce Klein. Adaptive Immunity to Fungi. Annu Rev Immunol. 2012; 30: 115-148.
 
[38]  Bourgeois, C., Majer, O., Frohner, I. E., Tierney, L. & Kuchler, K. Fungal attacks on mammalian hosts: pathogen elimination requires sensing and tasting. Curr. Opin. Microbiol. 2010; 13:401-408.
 
[39]  Iliyan D. Iliev, Vincent A. Funari, Kent D. Taylor, Quoclinh Nguyen, Christopher N. Reyes, Samuel P. Strom, Jordan Brown, Courtney A. Becker, Phillip R. Fleshner, Marla Dubinsky, Jerome I. Rotter, Hanlin L. Wang, Dermot P.B. McGovern, Gordon D. Brown, and David M. Underhill. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012 June 8; 336(6086): 1314-1317.
 
[40]  Christoph Mueller-Loebnitz, Helmut Ostermann, Anke Franzke, Juergen Loeffler, Lutz Uharek, Max Topp, and Hermann Einsele. Immunological Aspects of Candida and Aspergillus Systemic Fungal Infections. Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 102934, 7 pages.
 
[41]  Carvalho, A. et al. Polymorphisms in Toll-like receptor genes and susceptibility to pulmonary aspergillosis. J. Infect. Dis. 2008; 197: 618-621.
 
[42]  Said-Sadier, N., Padilla, E., Langsley, G. & Ojcius, D. M. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS ONE 2010; 5: e10008.
 
[43]  Karina Vega and Markus Kalkum Chitin, Chitinase Responses, and Invasive Fungal Infections. International Journal of Microbiology Volume 2012, Article ID 920459, 10 pages.
 
[44]  Plantinga, T. S. et al. Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. J. Acquir. Immune Defic. Syndr. 2010; 55: 87-94.
 
[45]  Cunha, C. et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116: 5394-5402.
 
[46]  Garcia-Solache, M. A. & Casadevall, A. Global warming will bring new fungal diseases for mammals. M Bio 2010; 1: e00061-10.
 
[47]  Marr K. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Cur Opin Oncol. 2010; 22:138-142.
 
[48]  Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007; 25(34): 5471-5489.
 
[49]  Maschmeyer G, Patterson T. New immunosuppressive agents and risk for invasive fungal infections. Curr Infec Dis Reps. 2009; 11:435-438.
 
[50]  Caira M, Girmenia C, Maria R, et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hematopoietic stem cell transplant: who is at highest risk? Eur J Haem. 2008; 81:242-243.
 
[51]  Partridge-Hinckley K, Liddell GM, Almyroudis NG, Segal BH. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathol. 2009; 168:329-337.
 
[52]  Diaz-Arevalo D, Bagramyan K, Hong TB et al. CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect. Immun. 2011; 79(6): 2257-2266.
 
[53]  Liu M, Capilla J, Johansen ME et al. Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again? J. Med. Microbiol. 2011; 60(Pt 10):1423-1432 (2011).